June 5, 2018 / 12:43 PM / 2 months ago

BRIEF-Tesaro Announces Collaboration To Evaluate Zejula In Combination With Anti-PD-L1 Cancer Immunotherapy, MEK Inhibitor In Platinum-Sensitive Ovarian Cancer

June 5 (Reuters) - Tesaro Inc:

* TESARO ANNOUNCES COLLABORATION TO EVALUATE ZEJULA® IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY AND MEK INHIBITOR IN PLATINUM-SENSITIVE OVARIAN CANCER

* CO AND GENENTECH ALSO WORKING TO EVALUATE COMBINATION OF ZEJULA AND ATEZOLIZUMAB IN PATIENTS WITH METASTATIC BLADDER CANCER

* PLANNED TRIAL WILL BE CONDUCTED BY GENENTECH AND IS EXPECTED TO BEGIN BY END OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below